Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
72-hour iloprost infusion in mechanically ventilated patients with infectious pulmonary endotheliopathy
2022-004079-17Phase 2Active
- Sponsor
- Rigshospitalet
- Start
- Feb 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Pulmonary endotheliopathy and respiratory failure comparing Ilomedin 72-hour infusion with Placebo 72-hour infusion (2 arms). Primary endpoint: 28-day all cause mortality. Started Feb 2023; status: active.
02
Drugs
iloprost
03
Conditions
Pulmonary endotheliopathyrespiratory failure
Beyond the preview
Go deeper on 2022-004079-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-004079-17.